What makes the Alluvi formulation different?
Alluvi describes its solution process as being designed to keep its research APIs within a controlled formulation environment from filling through storage. The Retatrutide 40mg pen studied here was independently analysed by Janoshik for concentration, purity and pH.
Alluvi subjected the prepared pen to a reported extended room-temperature study and compared analytical results across the study timeline.
Results at a glance
Study timeline
Initial analytical checkpoint
A Retatrutide 40mg Alluvi pen with a stated 2.4mL fill was assessed during the first stage of the study.
- Concentration: 16.00 mg/mL and 16.01 mg/mL
- Purity: 99.651% and 99.592%
- Calculated content: 38.40mg at 16.00 mg/mL × 2.4mL
- Janoshik Task: #147173
- Analysis date: 20 April 2026
Later analytical checkpoint
The later samples were held in Janoshik custody at room temperature before analysis on 19 May 2026.
- Concentration: 15.99 mg/mL
- Purity: 98.322%
- Calculated content: approximately 38.38mg at 15.99 mg/mL × 2.4mL
- pH: 7.66
- Documented Janoshik room-temperature custody: 33 days
- Janoshik Tasks: #165632 and #165637
Side-by-side analytical results
| Measurement | Initial checkpoint | Later checkpoint |
|---|---|---|
| Retatrutide concentration | 16.00 / 16.01 mg/mL | 15.99 mg/mL |
| Calculated content at 2.4mL | 38.40mg* | ≈38.38mg* |
| Purity | 99.651% / 99.592% | 98.322% |
| pH | Not shown on initial report | 7.66 |
*Calculated from the Janoshik-reported concentration using the stated 2.4mL fill volume. The calculated total content is not a separate laboratory measurement.
Independent Janoshik reports
The original report images are reproduced below so the analytical results, task numbers, batch information and laboratory comments can be reviewed directly. Select an image to open the full-size report.
Initial concentration & purityTask #147173 • Batch AR1739JAT
Later concentration & purityTask #165632 • Batch AR1739JAT
Later pH measurementTask #165637 • Batch AR1739JATUnderstanding the 56-day timeline
The 56-day room-temperature period is the overall study timeline stated by Alluvi. The later Janoshik reports specifically record that the samples were received on 16 April 2026 and held in Janoshik custody at room temperature until testing on 19 May 2026, giving a documented laboratory custody period of 33 days.
Keeping these two points separate allows the overall study timeline to be presented while accurately reflecting what the independent laboratory reports themselves document.
Research-use disclaimer
This page presents analytical information for laboratory research and development context only. It does not provide medical advice, treatment guidance, dosing information, administration instructions or reconstitution instructions.
The analytical results shown do not establish clinical safety, sterility, efficacy, suitability for injection or an authorised shelf life. Products referenced on this website are intended for research and development purposes only and are not intended for human or veterinary use.